source
- Radiopharma maker AdvanCell hauls in $315M for Pluvicto challengerAdvanCell raised a $315 million Series D to study a lead-based prostate cancer agent and shore up its US manufacturing of the radioactive treatment. The round marks one of the largest yet for a rad…Endpoints · 14d ago↗ source
- Kelun’s Merck-partnered ADC notches late-stage NSCLC win alongside KeytrudaThe Phase 3 results are the first direct proof-of-concept for an ADC replacing platinum-based chemo in a first-line standard-of-care regimen for non-small cell lung cancer, according to Leerink Par…BioSpace · 14d ago↗ source
- J&J touts Icotyde prescriptions, but not sales, in first full quarterJohnson & Johnson teased some details on Wednesday morning about how the launch of its expected blockbuster Icotyde performed in the second quarter. Without disclosing how much revenue the plaque p…